Capadenoson (BAY68-4986)
Phase 2Small molecule
BayerCapadenoson (BAY68-4986) is one of 60 small molecule programs targeting Angina Pectoris. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
376 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Capadenoson (BAY68-4986)
BayerPhase 2
Brukinsa
BBeOne Medicines
Preclinical
Romazicon
CConrado Roberto Hoffmann Filho
Preclinical
Anticoagulants
SanofiPreclinical
SGLT2 Inhibitor
Eli LillyPreclinical
Direct Anticoagulant
BayerPreclinical
Magnesium SO4
HHospital de Base
Preclinical
Anticoagulation
HHospital Álvaro Cunqueiro
Preclinical
Medication
NNYU Langone Health
Preclinical
Bupivacain
IIstanbul University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Capadenoson (BAY68-4986). EMBL-EBI & Wellcome Sanger Institute.
- [4]